Skip to main content
PharmSpace

Leukotriene receptor antagonists · Respiratory

Montelukast

Singulair®(brand names vary by market)

A tablet for asthma, with a warning most patients are never given.

Illustration of Montelukast as a tabletMON

Also: oral liquid

Mechanism

Cysteinyl leukotriene receptor antagonist: blocks the bronchoconstriction, mucus secretion and eosinophil recruitment driven by the leukotriene arm of arachidonic acid metabolism.

Indications

  • Asthma, as add-on controller
  • Exercise-induced bronchoconstriction
  • Allergic rhinitis
  • Aspirin-exacerbated respiratory disease

Formulations

TabletOral liquid

Dosing concepts

Add-on, not replacement

It is weaker than an inhaled corticosteroid and does not replace one in persistent asthma.

Timing

Taken in the evening, which suits the nocturnal pattern of asthma symptoms.

Concepts, not prescribing instructions. Practice numbers live in current references and local protocols.

Pharmacokinetics

Bioavailability
~64%
Half-life
2.7 to 5.5 h
Elimination
hepatic: CYP2C8 and 3A4; biliary excretion
Protein binding
>99%
Play with these concepts in the PK Lab

Adverse effects

  • Headachecommon
  • Neuropsychiatric eventsseriousAgitation, aggression, nightmares, depression and suicidality. A boxed warning in several jurisdictions and disproportionately reported in children.
  • Abdominal paincommon

Contraindications & precautions

Contraindications

  • Not for acute bronchospasm

Precautions

  • Existing psychiatric illness
  • Children and adolescents

Interactions

No curated interaction entries yet for this agent.

Monitoring

Mood, sleep and behaviour

The neuropsychiatric warning, which is routinely not passed on · Ask at every review, and ask the parent

Asthma control

If it is not helping after a fair trial, stop it

Counselling points

  • Take it in the evening.
  • It is a preventer, not a reliever.
  • Tell us straight away about changes in mood, sleep, nightmares, or unusual behaviour. This is a recognised effect and a reason to stop.
  • Parents: watch for irritability, low mood or aggression in a child taking this.

Clinical pearls

  • The neuropsychiatric warning is the single most important counselling point for this drug and the one most often omitted. Families frequently only connect the symptoms after it is raised.
  • It genuinely shines in aspirin-exacerbated respiratory disease and in exercise-induced symptoms, where the mechanism matches the trigger.

References & review

  • Montelukast product monograph (consult the current version for your market) (monograph)
  • Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. (reference-work)

Last reviewed 2026-08-16 · jurisdiction: global · drug information changes; verify against current references before practice use.